Literature DB >> 8115069

Bone mineral density is reduced in female but not male subjects with Addison's disease.

C M Florkowski1, S J Holmes, J R Elliot, R A Donald, E A Espiner.   

Abstract

AIMS: Bone mineral density (BMD) may be potentially reduced in Addison's disease as a result of excessive glucocorticoid replacement, loss of adrenal androgens or concomitant gonadal or thyroid disease. We have examined clinical and biochemical parameters, and BMD in a group of subjects with Addison's disease.
METHODS: Fourteen patients (9 female mean age 56 years, 5 male mean age 56.6 years) with primary adrenocortical failure (median duration 8.5 yrs) on replacement therapy were studied. Four had hypothyroidism on thyroxine doses (0.1 to 0.15 mg/d). Seven of the 9 females were post menopausal. Mean plasma cortisol levels were calculated from at least five samples in each subject drawn between 3 and 5 hours post dose, and the cortisol replacement dose calculated per unit body mass (mg/kg). BMD was measured by dual energy X-ray absorptiometry (DEXA) at femoral neck and lumbar spine (L2-4) and compared with local reference data.
RESULTS: For women (n = 9) at L2-4 the mean Z score was -1.21 (95% CI -1.69, -0.73), and at femoral neck -0.57 (95% CI -1.15, 0.00). For men (n = 5) at L2-4, the mean Z score was 1.32 (95% CI -0.86, 3.50) and at femoral neck 0.62 (95% CI -0.18, 1.42). For all patients, there was no significant correlation between mean plasma cortisol and Z scores at L2-4 and femoral neck, r = -0.003 and -0.095 respectively; and between duration of Addison's disease and mean Z scores at L2-4 and femoral neck r = -0.043 and 0.143 respectively.
CONCLUSIONS: Women with Addison's disease therefore have a greater than expected reduction in BMD. We postulate that this may be related to loss of adrenal androgens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8115069

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  10 in total

1.  Co-morbidities, management and clinical outcome of auto-immune Addison's disease.

Authors:  Lalantha Leelarathna; Louise Breen; James K Powrie; Stephen M Thomas; Rustom Guzder; Barbara McGowan; Paul V Carroll
Journal:  Endocrine       Date:  2010-07-03       Impact factor: 3.633

2.  Cortisol-dependent stress effects on cell distribution in healthy individuals and individuals suffering from chronic adrenal insufficiency.

Authors:  Ashley M Geiger; Kenneth P Pitts; Joachim Feldkamp; Clemens Kirschbaum; Jutta M Wolf
Journal:  Brain Behav Immun       Date:  2015-07-14       Impact factor: 7.217

3.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.

Authors:  Valentina Camozzi; Corrado Betterle; Anna Chiara Frigo; Veronica Zaccariotto; Martina Zaninotto; Erica De Caneva; Paola Lucato; Walter Gomiero; Silvia Garelli; Chiara Sabbadin; Monica Salvà; Miriam Dalla Costa; Marco Boscaro; Giovanni Luisetto
Journal:  Endocrine       Date:  2017-08-09       Impact factor: 3.633

4.  Use of steroid profiles in determining the cause of adrenal insufficiency.

Authors:  Jennifer P Holst; Steven J Soldin; Rochelle E Tractenberg; Tiedong Guo; Priya Kundra; Joseph G Verbalis; Jacqueline Jonklaas
Journal:  Steroids       Date:  2006-12-08       Impact factor: 2.668

5.  Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters.

Authors:  N Alonso; M L Granada; A Lucas; I Salinas; J Reverter; A Oriol; A Sanmarti
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 6.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

7.  Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey.

Authors:  M Forss; G Batcheller; S Skrtic; G Johannsson
Journal:  BMC Endocr Disord       Date:  2012-06-13       Impact factor: 2.763

8.  Significance of dopamine D1 receptor signalling for steroidogenic differentiation of human induced pluripotent stem cells.

Authors:  Koji Matsuo; Masakatsu Sone; Kyoko Honda-Kohmo; Takafumi Toyohara; Takuhiro Sonoyama; Daisuke Taura; Katsutoshi Kojima; Yorihide Fukuda; Youichi Ohno; Mayumi Inoue; Akira Ohta; Kenji Osafune; Kazuwa Nakao; Nobuya Inagaki
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

9.  Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency.

Authors:  Valentina Guarnotta; Claudia Di Stefano; Carla Giordano
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

10.  Residual Adrenal Function in Autoimmune Addison's Disease-Effect of Dual Therapy With Rituximab and Depot Tetracosactide.

Authors:  Catherine Napier; Earn H Gan; Anna L Mitchell; Lorna C Gilligan; D Aled Rees; Carla Moran; Krishna Chatterjee; Bijay Vaidya; R Andrew James; Yaasir Mamoojee; Simon Ashwell; Wiebke Arlt; Simon H S Pearce
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.